N. Yu. Koroleva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
N. Yu. Koroleva has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alexander D. Korotkov
N.P. Bechtereva Institute of the Human Brain, Russian Academy of Sciences, St. Petersburg, Russia
2 shared publications - N. V. Muzhikina
Center of Epileptology and Video-EEG Monitoring, Institute of Human Brain, Russian Academy of Sciences
2 shared publications - A. B. Dmitriev
Federal Neurosurgical Center, Ministry of Health of the Russia
1 shared publication - A. V. Markin
Svt. Luka’s Institute of Child and Adult Neurology and Epilepsy
1 shared publication - Anna A. Feygina
Medical Affairs International, Neuromodulation LivaNova PLC London UK
1 shared publication - Anna A. Usoltseva
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by National Association of Neurologists in NATIONAL JOURNAL OF NEUROLOGY
- Vol. 1 (27) , 18-25
The Close Relationship Between Apnea, Epilepsy and SUDEP
A review of recent publications about sleep apnea and epilepsy has been shown that the respiratory system plays a crucial role in the development of sudden unexpected death in epilepsy (SUDEP). Sleep apnea can provoke or worsen epilepsy, and treatment of sleep apnea can reduce the number of seizures. The International Antiepileptic League identifies a special group of sleep-related epilepsies (sleep-accentuated epilepsies; sleep-associated epilepsies; epilepsy of awakening), among which, first of all, apnea screening should be carried out. In patients with apnea and epilepsy, the use of medications and therapies that cause or exacerbate apnea attacks should be limited. Apnea therapy should be used in a comprehensive and individualized way, in particular, treatment of obesity, CPAP therapy, sultiam (from 200 mg/day for adult patients with apnea and epilepsy), treatment of ENT pathology, etc. are recommended.
- 30 June 2025
- Published by National Association of Neurologists in NATIONAL JOURNAL OF NEUROLOGY
- Vol. 1 (27) , 18-25
Open AccessThe Close Relationship Between Apnea, Epilepsy and SUDEP
A review of recent publications about sleep apnea and epilepsy has been shown that the respiratory system plays a crucial role in the development of sudden unexpected death in epilepsy (SUDEP). Sleep apnea can provoke or worsen epilepsy, and treatment of sleep apnea can reduce the number of seizures. The International Antiepileptic League identifies a special group of sleep-related epilepsies (sleep-accentuated epilepsies; sleep-associated epilepsies; epilepsy of awakening), among which, first of all, apnea screening should be carried out. In patients with apnea and epilepsy, the use of medications and therapies that cause or exacerbate apnea attacks should be limited. Apnea therapy should be used in a comprehensive and individualized way, in particular, treatment of obesity, CPAP therapy, sultiam (from 200 mg/day for adult patients with apnea and epilepsy), treatment of ENT pathology, etc. are recommended.
- Open Access
- 16 March 2023
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 28 (1) , 62-66
Structural epilepsy in a patient with multiple sclerosis
Clinical case of structural epilepsy in a patient with multiple sclerosis is presented, which shows the achievement of seizure’s stable remission, which is extremely rare in forms of epilepsy with a multi-focal lesion another etiology and a long history of the disease without combination with multiple sclerosis. Video-EEG monitoring, positron emission tomography of the brain with 18F-deoxyglucose, expand the possibilities of diagnosing form of epilepsy in patients with combined pathology, which allows prescribing adequate therapy.
- 16 March 2023
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 28 (1) , 62-66
Open AccessStructural epilepsy in a patient with multiple sclerosis
Clinical case of structural epilepsy in a patient with multiple sclerosis is presented, which shows the achievement of seizure’s stable remission, which is extremely rare in forms of epilepsy with a multi-focal lesion another etiology and a long history of the disease without combination with multiple sclerosis. Video-EEG monitoring, positron emission tomography of the brain with 18F-deoxyglucose, expand the possibilities of diagnosing form of epilepsy in patients with combined pathology, which allows prescribing adequate therapy.
- Open Access
- 18 January 2023
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 14 (4) , 344-354
Clinical case of a patient with focal cortical dysplasia IIa adjacent to the speech center: diagnostic and therapeutic algorithms
A clinical case of a patient with pharmacoresistant epilepsy due to focal cortical dysplasia (PCD) directly adjacent to the speech zone in the left temporal region is presented. The diagnostic search and transition from MRI-negative form to structural focal epilepsy progressed for more than 6 years. It was accounted for by the fact that type IIa vs. IIb FCD is visualized much worse, magnetic resonance imaging (MRI) signs of type IIa FCD are not so prominent, so that this type of dysplasia is often omitted. Functional research methods in epileptology, such as video-electroencephalography monitoring, brain positron emission tomography with 18F-fluorodeoxyglucose, functional MRI of speech zones, allow to more accurately verify the form of epilepsy and determine a scope of surgical treatment. Surgical intervention in carefully selected patients may contribute to favorable outcome of epilepsy (Engel 1, 51-months follow-up), which will lead to improved quality of life.
- 18 January 2023
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 14 (4) , 344-354
Open AccessClinical case of a patient with focal cortical dysplasia IIa adjacent to the speech center: diagnostic and therapeutic algorithms
A clinical case of a patient with pharmacoresistant epilepsy due to focal cortical dysplasia (PCD) directly adjacent to the speech zone in the left temporal region is presented. The diagnostic search and transition from MRI-negative form to structural focal epilepsy progressed for more than 6 years. It was accounted for by the fact that type IIa vs. IIb FCD is visualized much worse, magnetic resonance imaging (MRI) signs of type IIa FCD are not so prominent, so that this type of dysplasia is often omitted. Functional research methods in epileptology, such as video-electroencephalography monitoring, brain positron emission tomography with 18F-fluorodeoxyglucose, functional MRI of speech zones, allow to more accurately verify the form of epilepsy and determine a scope of surgical treatment. Surgical intervention in carefully selected patients may contribute to favorable outcome of epilepsy (Engel 1, 51-months follow-up), which will lead to improved quality of life.
- Open Access
- 21 July 2021
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 13 (2) , 106-122
Efficacy and safety of using vagus nerve stimulation in patients with pharmacoresistant epilepsy in the Russian Federation: a multi-center retrospective observational program
Objective: to assess efficacy and safety of vagus nerve stimulation (VNS) in patients with pharmacoresistant epilepsy.Material and methods. A multi-center retrospective observational program was applied in patients with pharmacoresistant epilepsy by using vagus nerve stimulation for at least 2 years. There were enrolled 151 subjects, patient age on stimulator implantation varied from 5 to 65 years (24.4±13.1 years). Among them, subjects under 18 or at least 18 years of age comprised 58 (38.4%) and 93 (61.6%), respectively. Changes in rate and severity of major group epileptic seizures (highly disabling type) 24 months after VNS-therapy vs. baseline state as well as during 3-, 6-, 9-, 12-month follow-up were compared. There were assessed stimulator-related effects on VNS-therapy as well as patient quality of life 2 years after therapy. The dynamics of the frequency of all types of epileptic seizures was evaluated according to McHugh Outcome scale.Results. Mean epilepsy duration on stimulator implantation was 170.9±126.8 months, with maximum up to 666 months (55 years). Number of patients with dominant (disabling) seizures on implantation procedure comprised 136 (90.1%). Decline in dominant epileptic seizure rate by 50–99% was recorded in 91 patients (66.9%) 24 months after VNStherapy. Among such subjects were 41 patients (30.15%) featured with disabling seizures including 24 fully seizure free subjects (17.65%). Decreased rate of all group epileptic seizures by more than 50% (responders) was found in 52.9% cases, including subjects under 18 and adults in 63.9% and as few as 46.3% (pConclusion. Vagus nerve stimulation is an effective and safe auxiliary treatment method for therapy of pharmacoresistant epilepsy both in children and adults.
- 21 July 2021
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 13 (2) , 106-122
Open AccessEfficacy and safety of using vagus nerve stimulation in patients with pharmacoresistant epilepsy in the Russian Federation: a multi-center retrospective observational program
Objective: to assess efficacy and safety of vagus nerve stimulation (VNS) in patients with pharmacoresistant epilepsy.Material and methods. A multi-center retrospective observational program was applied in patients with pharmacoresistant epilepsy by using vagus nerve stimulation for at least 2 years. There were enrolled 151 subjects, patient age on stimulator implantation varied from 5 to 65 years (24.4±13.1 years). Among them, subjects under 18 or at least 18 years of age comprised 58 (38.4%) and 93 (61.6%), respectively. Changes in rate and severity of major group epileptic seizures (highly disabling type) 24 months after VNS-therapy vs. baseline state as well as during 3-, 6-, 9-, 12-month follow-up were compared. There were assessed stimulator-related effects on VNS-therapy as well as patient quality of life 2 years after therapy. The dynamics of the frequency of all types of epileptic seizures was evaluated according to McHugh Outcome scale.Results. Mean epilepsy duration on stimulator implantation was 170.9±126.8 months, with maximum up to 666 months (55 years). Number of patients with dominant (disabling) seizures on implantation procedure comprised 136 (90.1%). Decline in dominant epileptic seizure rate by 50–99% was recorded in 91 patients (66.9%) 24 months after VNStherapy. Among such subjects were 41 patients (30.15%) featured with disabling seizures including 24 fully seizure free subjects (17.65%). Decreased rate of all group epileptic seizures by more than 50% (responders) was found in 52.9% cases, including subjects under 18 and adults in 63.9% and as few as 46.3% (pConclusion. Vagus nerve stimulation is an effective and safe auxiliary treatment method for therapy of pharmacoresistant epilepsy both in children and adults.